Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

Sensor-augmented insulin-pump therapy effective for type 1 diabetes patients

Adding a continuous blood sugar level sensor to an insulin pump helps patients with type 1 diabetes achieve better blood sugar control compared to the common standard of care, multiple daily insulin injections, concludes a study published on-line today in the New England Journal of Medicine.

2 Jul 2010

Endo responds to FDA Complete Response letter for FORTESTA NDA

Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.

1 Jul 2010

AMS granted 510(k) clearance for MoXy Liquid Cooled Fiber

American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the 510(k) clearance of its revolutionary MoXy™ Liquid Cooled Fiber.

1 Jul 2010

Sensor integrated insulin pump for better blood sugar control

30 Jun 2010

FDA grants AMS clearance for MiniArc Precise Single-Incision Sling System

American Medical Systems® (AMS), a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the Food and Drug Administration (FDA) has cleared the MiniArc® Precise Single-Incision Sling System, a product for the treatment of female stress urinary incontinence (SUI). MiniArc Precise is the next generation sling in the MiniArc family sling system, the number one selling single-incision sling in the United States.

29 Jun 2010

Medicare to use new fraud identification tool

Gov Info Security: "The Centers for Medicare & Medicaid Services is the first agency to use a new fraud mapping tool that ultimately will be used throughout the federal government.

25 Jun 2010

Palatin announces completion of patient dosing, database lock in bremelanotide study for ED

Palatin Technologies, Inc. today announced the completion of patient dosing and database lock in a double-blind, placebo-controlled, multiple dose, crossover study of bremelanotide, its subcutaneously administered melanocortin agonist for treatment of erectile dysfunction (ED). Palatin expects to report top-line data in the next calendar quarter.

24 Jun 2010

Health Canada issues Screening Acceptance Letter in connection with NexMed's NDS for Vitaros

NexMed, Inc., a specialty CRO with a pipeline of product candidates based on the NexACT technology, today announced that Health Canada has confirmed acceptance of the Company's CMC response for review. The Screening Acceptance Letter from Health Canada was issued in connection with its New Drug Submission for Vitaros, the Company's topical treatment for erectile dysfunction.

24 Jun 2010

Data on Qnexa to be featured in six presentations at ADA annual meeting

VIVUS, Inc. today announced that data on Qnexa, an investigational drug candidate, will be featured in a total of six presentations – including an oral presentation, three moderated poster presentations and two poster presentations – during the 70th Scientific Sessions of the American Diabetes Association, being held from June 25-29, 2010 in Orlando, Florida.

22 Jun 2010

Most men admitted for heart attack had erectile dysfunction

Seven out of 10 men admitted to hospital for a heart attack (acute ST segment elevation myocardial infarction (STEMI)) had erectile dysfunction (ED) in the six months prior to their admission according to new data presented today at the World Congress of Cardiology (WCC) Scientific Sessions in Beijing, China.

19 Jun 2010

Obesity linked to bad sexual health: French Study

Now French researchers have found a link between obesity and bad sexual health in their study of 12,364 men and women aged 18 to 69 ranging from normal weight to obese who lived in France in 2006.

17 Jun 2010

Scientists identify symptoms associated with late-onset hypogonadism

Scientists have for the first time identified the symptoms associated with what has been termed late-onset hypogonadism or 'male menopause' caused by a reduction in testosterone production in ageing men.

17 Jun 2010

VIVUS to present data on Qnexa at ENDO meeting

VIVUS, Inc. today announced that data on Qnexa, an investigational drug candidate, will be presented at the Endocrine Society's 92nd Annual Meeting and Expo in San Diego, California. Timothy Garvey, M.D., professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham and a Qnexa investigator, will deliver an oral presentation at the Clinical Trials Symposium on Saturday, June 19, entitled: "Once-Daily, Low-Dose, Controlled-Release Phentermine/Topiramate Demonstrates Significant Improvement in Weight, Related Risk in Overweight/Obese Patients with Comorbidities."

16 Jun 2010

NexMed provides update on Vitaros NDS with Health Canada

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today provided an update on the status of its New Drug Submission ("NDS") with Health Canada for Vitaros®, the Company's topical treatment for erectile dysfunction.

11 Jun 2010

Emerging health care models and approaches discussed at 2010 Health Care Conference

Dr. Sanford J. Siegel, president and CEO of Chesapeake Urology Associates, Maryland, was a featured panelist at the 2010 Health Care Conference for health care community executives, held at the BWI Marriott in Baltimore on June 7, 2010.

10 Jun 2010

Therapies for female sexual dysfunction

Many women experience problems in the bedroom at one time or another. Female sexual dysfunction is not uncommon and although some women and healthcare providers have difficulty discussing it, it has been recognized by the medical community for decades. In fact, for the last twenty years, it has been listed in the Diagnostic and Statistical Manual of Mental Disorders, a manual published by the American Psychiatric Association, used to classify and diagnose psychological disorders.

10 Jun 2010

Sonic hedgehog helps regenerate critical nerve that runs along prostate: Research

After men have surgery to remove a cancerous prostate gland, up to 80 percent of them will lose the ability to have an erection because of damage to a critical nerve that runs along the prostate.

9 Jun 2010

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

VIVUS, Inc. today announced that data from a previously reported phase 2 study evaluating the safety and efficacy of the investigational drug Qnexa for the treatment of obstructive sleep apnea were presented at SLEEP 2010, the 24th Annual Meeting of the Associated Professional Sleep Societies.

8 Jun 2010

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

VIVUS, Inc. today announced positive results from the phase 3 REVIVE-Diabetes (TA-302) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED) in men with type 1 and type 2 diabetes. The REVIVE-Diabetes study met all three primary endpoints across the two doses studied by demonstrating statistically significant improvement in erectile function as measured by the Sexual Encounter Profile (SEP) and improvements in the International Index of Erectile Function (IIEF) score.

7 Jun 2010

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

3 Jun 2010